Boehringer to settle blood thinner drug suits for $650m


German-based firm Boehringer-Ingelheim has committed $650 million (£390 million) to settle around 4000 US court cases relating to its anticoagulant stroke prevention drug Pradaxa (dabigatran).

The patients bringing the lawsuits claim that the drug caused serious, and even fatal, bleeding. However, the US Food and Drugs Administration has backed up Boehringer’s view on Pradaxa’s risk-benefit profile compared to Warfarin, the established standard treatment. A study of 134,000 US patients found that, although Pradaxa is associated with an increased risk of major gastrointestinal bleeding, it presents no greater risk of heart attacks, and is more effective at preventing clot-related strokes, bleeding in the brain and death.

Boehringer lawyer Andreas Neumann said in a statement that the company expects most of the plaintiffs to accept the settlement. He stated that the company was confident it should win the suits based on its evidence, but explained that ‘we have to consider that juries composed of lay people have to decide about very difficult scientific matters. This does not allow reliable predictions for the outcome of a huge number of individual trials. This settlement allows our company to avoid the distraction and uncertainty of protracted litigation.’


Related Content

Dow settles remaining polyurethane price-fixing suits

11 April 2016 Business

news image

$400m proposal covers claims of customers not involved in previous class action lawsuit

Takeda offers $2.4bn to settle diabetes litigation

11 May 2015 Business

news image

Aims to settle multiple outstanding lawsuits relating to Actos (pioglitazone) and bladder cancer

Most Commented

New antibiotic picked from nose bacteria

27 July 2016 Research

news image

Discovery suggests human microbiome may be an untapped source of antimicrobial compounds

Perovskite boosts silicon solar cell efficiency

25 November 2015 News and Analysis

news image

Silicon industry will be ‘beating a path to the door’ of inventors, says scientist